Literature DB >> 27063273

Effect of Weight Loss, Diet, Exercise, and Bariatric Surgery on Nonalcoholic Fatty Liver Disease.

William N Hannah1, Stephen A Harrison2.   

Abstract

Nonalcoholic fatty liver disease (NAFLD) is the hepatic manifestation of the metabolic syndrome. NAFLD is the most common liver disease in developed countries. Weight reduction of 3% to 5% is associated with improved steatosis; reductions of 5% to 7% are necessary for decreased inflammation; with 7% to 10%, individuals may experience NAFLD/NASH remission and regression of fibrosis. No specific dietary intervention has proven beneficial beyond calorie restriction. Physical activity without weight loss seems to decrease hepatic steatosis. Bariatric surgery is associated with decreased cardiovascular risk and improved overall mortality in addition to reduction in hepatic steatosis, inflammation, and fibrosis. Published by Elsevier Inc.

Entities:  

Keywords:  Bariatric surgery; Diet; Exercise; Nonalcoholic fatty liver disease; Weight loss

Mesh:

Substances:

Year:  2016        PMID: 27063273     DOI: 10.1016/j.cld.2015.10.008

Source DB:  PubMed          Journal:  Clin Liver Dis        ISSN: 1089-3261            Impact factor:   6.126


  41 in total

1.  Lifestyle Interventions Beyond Diet and Exercise for Patients With Nonalcoholic Fatty Liver Disease.

Authors:  James Philip Esteban; Amreen Dinani
Journal:  Gastroenterol Hepatol (N Y)       Date:  2020-03

Review 2.  Gastric Bypass and Influence on Improvement of NAFLD.

Authors:  Vamsi Alli; Ann M Rogers
Journal:  Curr Gastroenterol Rep       Date:  2017-06

3.  Non-alcoholic fatty liver disease: beyond the liver is an emerging multifaceted systemic disease.

Authors:  Luigi Elio Adinolfi; Aldo Marrone; Luca Rinaldi
Journal:  Hepatobiliary Surg Nutr       Date:  2018-04       Impact factor: 7.293

4.  Serum Plant Sterols Associate with Gallstone Disease Independent of Weight Loss and Non-Alcoholic Fatty Liver Disease.

Authors:  Pirjo Käkelä; Ville Männistö; Imre Ilves; Maija Vaittinen; Milla-Maria Tauriainen; Matti Eskelinen; Helena Gylling; Hannu Paajanen; Jussi Pihlajamäki
Journal:  Obes Surg       Date:  2017-05       Impact factor: 4.129

5.  Intentional weight loss, weight cycling, and endometrial cancer risk: a systematic review and meta-analysis.

Authors:  Xiaochen Zhang; Jennifer Rhoades; Bette J Caan; David E Cohn; Ritu Salani; Sabrena Noria; Adrian A Suarez; Electra D Paskett; Ashley S Felix
Journal:  Int J Gynecol Cancer       Date:  2019-08-26       Impact factor: 3.437

Review 6.  Prevention of Hepatocellular Carcinoma.

Authors:  Kerstin Schütte; Fathi Balbisi; Peter Malfertheiner
Journal:  Gastrointest Tumors       Date:  2016-08-18

7.  Targeting the mitochondrial pyruvate carrier attenuates fibrosis in a mouse model of nonalcoholic steatohepatitis.

Authors:  Kyle S McCommis; Wesley T Hodges; Elizabeth M Brunt; Ilke Nalbantoglu; William G McDonald; Christopher Holley; Hideji Fujiwara; Jean E Schaffer; Jerry R Colca; Brian N Finck
Journal:  Hepatology       Date:  2017-03-30       Impact factor: 17.425

8.  Probiotics administration following sleeve gastrectomy surgery: a randomized double-blind trial.

Authors:  S Sherf-Dagan; S Zelber-Sagi; G Zilberman-Schapira; M Webb; A Buch; A Keidar; A Raziel; N Sakran; D Goitein; N Goldenberg; J A Mahdi; M Pevsner-Fischer; N Zmora; M Dori-Bachash; E Segal; E Elinav; O Shibolet
Journal:  Int J Obes (Lond)       Date:  2017-08-30       Impact factor: 5.095

9.  Comparison of Early Morbidity and Mortality Between Sleeve Gastrectomy and Gastric Bypass in High-Risk Patients for Liver Disease: Analysis of American College of Surgeons National Surgical Quality Improvement Program.

Authors:  Mohamad A Minhem; Sali F Sarkis; Bassem Y Safadi; Souha A Fares; Ramzi S Alami
Journal:  Obes Surg       Date:  2018-09       Impact factor: 4.129

Review 10.  NAFLD in children: new genes, new diagnostic modalities and new drugs.

Authors:  Valerio Nobili; Anna Alisi; Luca Valenti; Luca Miele; Ariel E Feldstein; Naim Alkhouri
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2019-07-05       Impact factor: 46.802

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.